Who’s Going to Antibody Engineering 2026
Dec 13–16, 2026 San Diego, CA ~900 attendees Website
168 companies and 131 speakers at Antibody Engineering 2026, a ~900-person, mostly biopharma meeting of antibody and protein engineers. As of Nov 10, 2026.
| Organization | Antibody Engineering 2026 Attendance |
|---|---|
Xencor Pasadena, CA | |
Develops engineered antibodies using its XmAb Fc and bispecific technologies, for cancer and autoimmune diseases. | Chair Sun Dec 13 1:00pm–1:15pm Talk Sun Dec 13 4:15pm–5:00pm Chair Mon Dec 14 8:00am–8:05am Talk Mon Dec 14 10:55am–11:30am Chair Wed Dec 16 8:10am–8:15am Talk Wed Dec 16 9:15am–9:45am XenLock™ Fab domains for controlled heavy-light chain pairing in native-like 1+1 bispecific antibodies with extended half-life Redesigned antibody arms that pair only with their intended partner, used to build two-target antibodies that last longer in blood. Bispecifics & multispecifics |
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company developing antibodies, antibody-drug conjugates and multispecifics in oncology and other diseases. | Talk Sun Dec 13 11:00am–11:45am Keynote Mon Dec 14 10:20am–10:55am From Insight to Impact: Translational Medicine as a Driver of ADC Clinical Success and Future Innovation Why finding biological markers of response early helps antibodies carrying a cell-killing drug succeed in patients. ADCs & conjugates Talk Wed Dec 16 10:30am–11:00am CD8-Guided T Cell Engager with Potent Preclinical Efficacy and Superior Therapeutic Index An antibody that pulls killer T cells onto liver cancer cells while rousing fewer of the T cells that drive dangerous immune reactions. Chair Wed Dec 16 2:10pm–2:15pm Talk Wed Dec 16 2:15pm–2:45pm |
Amgen Thousand Oaks, CA | |
Global biopharmaceutical company developing and manufacturing biologic medicines, including bispecific T-cell engagers. | Chair Sun Dec 13 1:00pm–1:15pm Talk Sun Dec 13 1:15pm–1:45pm Developability-Guided Generative Biology for Therapeutic Protein Engineering Designing new therapeutic proteins by computer while checking from the start that they can be made and purified. AI & computational design Talk Sun Dec 13 4:15pm–5:00pm Talk Mon Dec 14 5:45pm–6:15pm Induced Proximity and Next-Generation Antibody Therapeutics Bispecifics & multispecifics |
Genentech South San Francisco, CA | |
Biotechnology company and Roche Group member that discovers, develops and markets antibody and other medicines. | Talk Sun Dec 13 11:00am–11:45am Talk Mon Dec 14 2:30pm–3:00pm Dissecting the Mechanisms of Action of PROTABs: Insights into Designing Antibody-Based Protein Degraders How the shape of antibody binding decides whether a target protein on the cell surface is actually destroyed. Bispecifics & multispecifics Chair Tue Dec 15 8:10am–8:15am Talk Tue Dec 15 8:15am–8:45am From COVID to Cancer: LNP-mRNA as an Antigen Format for Antibody Discovery Against Challenging Membrane Proteins Immunizing animals with mRNA packaged in tiny fat particles, so their antibodies recognize proteins embedded in cell membranes. Protein engineering |
Johnson & Johnson New Brunswick, NJ | |
Healthcare company whose Innovative Medicine segment develops antibodies, bispecifics and other medicines. | Talk Sun Dec 13 2:15pm–2:45pm Format Matters: Biophysical Characterization and Developability of Complex Biotherapeutics How a molecule's overall shape changes whether it can be made into a drug, across many measured antibody formats. Talk Mon Dec 14 10:55am–11:30am Chair Tue Dec 15 8:10am–8:15am |
Regeneron Tarrytown, NY | |
Biotechnology company that discovers, develops and markets antibody medicines, including bispecific antibodies, using its VelocImmune mouse platform. | Talk Sun Dec 13 3:45pm–4:15pm From Molecule Design to Approved Regimens: A Clinical Pharmacology Perspective on Dose Selection for Next-Generation Biologics How measurements of drug levels and effects in the body guide the first human dose and the final approved dosing schedule. Talk Mon Dec 14 5:15pm–5:45pm Targeting IgE Responses Beyond oncology Chair Wed Dec 16 8:10am–8:15am |
University of Southampton Southampton, United Kingdom | |
Public research university whose Centre for Cancer Immunology works on antibody immunotherapy and Fc receptor biology. | Chair Mon Dec 14 2:25pm–2:30pm Talk Mon Dec 14 4:45pm–5:15pm Disulfide Engineering of Immunostimulatory Antibodies for Augmented Receptor Agonism and Immune Cell Stimulation Adding chemical bridges between an antibody's two arms to lock its shape and make it switch on immune cells more strongly. Protein engineering Chair Tue Dec 15 8:10am–8:15am |
Alloy Therapeutics Waltham, MA | |
Provides ATX transgenic mice, display libraries and discovery services for antibodies and other drug modalities to drug developers. | Booth Exhibiting at Booth 220 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 1:45pm–2:15pm ATX-Gx Select: A New Mouse Strain That Can Identify Antigen Experienced B Cells in Situ to Facilitate Antibody Drug Discovery for Complex Therapeutic Targets New transgenic mouse strains that fluorescently mark antigen-experienced B cells, so antibodies against hard targets can be found without making the target protein. Antibody discovery Talk Wed Dec 16 7:30am–8:00am VHH and VLL Discovery Using ATX Transgenic Animals and Yeast Displayed Libraries Finding tiny single-piece human antibodies, using engineered mice and yeast-grown libraries, that can reach hidden pockets on a target. Antibody discovery |
RT Rondo Therapeutics Hayward, CA | |
Develops bispecific T cell engagers, including co-stimulatory CD28 bispecifics, for solid tumors. | Chair Sun Dec 13 9:00am–9:10am Session Co-Chair Welcome and Opening Remarks Short research talks by scientists within ten years of their graduate degree, plus career advice and time to meet peers. Chair Tue Dec 15 2:25pm–2:30pm Talk Tue Dec 15 2:30pm–3:00pm Combination of Signal 1 and Signal 2 T Cell Engagers for Treatment of Ovarian Cancer Pairing two antibodies that give T cells both of the signals they need, aiming at ovarian cancer that no longer responds to platinum drugs. Chair Wed Dec 16 8:10am–8:15am |
Twist Bioscience South San Francisco, CA | |
Synthetic DNA company whose biopharma unit provides antibody libraries and antibody discovery and optimization services. | Booth Exhibiting at Booth 200 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 12:15pm–1:15pm Scaling Wet-Lab Validation for AI-based Biologic Discovery Why lab testing has become the bottleneck for AI antibody design, and how a shared model platform from Eli Lilly connects to it. AI & computational designAntibody discovery Talk Tue Dec 15 1:40pm–2:00pm Screening in the Format You’ll Develop In: Cell-Free Expression of Full-Length IgG Making full-length antibodies without cells at screening scale, and how their binding compares with the same antibodies made in mammalian cells. Antibody discovery Talk Wed Dec 16 7:30am–8:00am Engineering for Better Bispecifics: Introducing the B-Body® Platform A two-target antibody design meant to assemble reliably, avoiding low yields and hard purification when production scales up. Bispecifics & multispecificsDevelopability & CMC |
Find buyers from companies at Antibody Engineering 2026
Tell us what you sell and we’ll find the people at these companies most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
When and where is Antibody Engineering 2026?
Antibody Engineering & Therapeutics 2026 runs December 13–16, 2026, at Marriott Marquis San Diego Marina in San Diego, CA.
What are the Antibody Engineering 2026 exhibit hall hours?
The exhibit hall is open Mon, Dec 14, 4:00pm–4:45pm; Tue, Dec 15, 9:45am–4:45pm.
Where is the Antibody Engineering 2026 program?
This guide lists every organization on the Antibody Engineering 2026 program with its sessions; the full program is on the official website.
How do I register for Antibody Engineering 2026?
Fees and registration are on the organizer's registration page.
What conference is this?
Antibody Engineering & Therapeutics is an annual meeting on antibody discovery and engineering, run with The Antibody Society and held December 13–16, 2026 at the Marriott Marquis San Diego Marina. It brings together antibody discovery, protein engineering and developability scientists from pharma, biotech and academia with the discovery-platform, reagent and instrument companies that serve them, across tracks on in vitro and in vivo discovery, bispecifics and multispecifics, cell engagers, antibody–drug conjugates, antibody interfaces and domains, difficult targets, and uses beyond oncology.
What is in this guide?
Every organization we can place at Antibody Engineering 2026: 131 speakers from the public program (134 sessions) rolled up to their companies and institutions, plus the 85 sponsors and exhibitors from the public directory with their booth numbers where published — 168 organizations in one list. Speakers appear as job titles, never by name.
How are organizations typed?
By the role an organization plays in antibody discovery and development: drug developers (large pharma and biotech), then the companies around them — CROs and CDMOs, discovery platforms, reagents, instruments and analytics, software and AI, consulting and other services — and academic, government and non-profit bodies. The topic filters come from the track a session sits in and from each session’s own title and abstract.
How current is it?
Pulled from the public agenda, speaker list and sponsor directory on November 10, 2026. Exhibit-hall hours are the first and last exhibit-hall activity on the public agenda.
Browse Antibody Engineering 2026 by
Organizations with their own page
106 organizations — every exhibitor and every organization with 2 or more presentations.
- A-Alpha Bio
- Ab Studio
- Ablexis AlivaMab
- ACROBiosystems
- Agilent
- Ajinomoto
- Alloy Therapeutics
- Amazon Web Services
- Amgen
- AntBio
- Antibody Design Labs
- Antibody Solutions
- Apoha
- argenx
- ARL Bio Pharma
- Asimov
- AstraZeneca
- Asymchem
- Atem Bio
- ATUM
- Aurigene Pharmaceutical Services
- Benchling
- Biocytogen
- Biointron
- Bionova Scientific
- Bon Opus Biosciences
- BPS Bioscience
- Bruker
- Carterra
- Celetrix
- Chai Discovery
- Chemical Computing Group
- Chugai Pharmaceutical
- City of Hope
- Cradle
- Creative Biolabs
- Cyagen
- Deeptope
- Dotmatics
- DPBIO
- Eleva
- emp BIOTECH
- Eton Bioscience
- evitria
- FairJourney Biologics
- Fluidic Sciences
- Fusion Antibodies
- Gator Bio
- GeneFrontier
- Genentech
- Genmab
- Genovac
- genOway
- GenScript
- Gyes
- Gyros Protein Technologies
- Harvard University
- iBody
- Invenra
- IQVIA
- Johnson & Johnson
- Kactus
- Lampire Biological Laboratories
- Liberum Bio
- Lonza
- Macaw Therapeutics
- MiLaboratories
- MindWalk
- NaturalAntibody
- Nicoya
- NJ Bio
- Nona Biosciences
- Nuclera
- OmniAb
- PAIA Biotech
- Partillion Bioscience
- Precision Antibody
- Precision BioTools
- Primrose Bio
- ProBio
- Promega
- Protein BioSolutions
- Proteina
- Regeneron
- Rigaku
- Rondo Therapeutics
- Sapidyne Instruments
- Schrödinger
- SeromYx Systems
- Siemens
- Sino Biological
- Specifica
- SPOC Proteomics
- StackWave
- Syngene International
- Thomson Instrument Company
- Twist Bioscience
- University of Michigan
- University of Southampton
- University of Texas at Austin
- Vivaproducts
- Wheeler Bio
- WuXi Biologics
- Xencor
- Yurogen Biosystems
- Zymeworks
Not affiliated with or endorsed by Antibody Engineering & Therapeutics, its organizers or The Antibody Society. Submit a correction